Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October

By Cory Renauer - Updated Nov 7, 2017 at 10:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Tiny start-up AnaptysBio helped spread fear that Dupixent's ongoing commercial launch might fizzle out.

What happened

Shares of Regeneron Pharmaceuticals Inc. (REGN -0.28%) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to data from S&P Global Market Intelligence, the stock slid 9.95% in October as investors fretted about Dupixent's ongoing commercial launch in light of surprisingly strong data from a potential competitor. 

So what 

Dupixent is a twice-monthly injection expected to generate around $5 billion in annual sales by 2022 as a treatment for patients with moderate to severe cases of eczema and hopefully asthma. In September, Regeneron and its big pharma partner, Sanofi (SNY -0.28%), released late-stage data from an asthma trial that was good but not great. The observed 46% annual attack rate reduction might earn an approval for the indication, but it wasn't dramatic enough to make a big splash in a pool crowded with effective treatment options.

Confused person watching his money being sucked down a hole.

Image source: Getty Images.

Regeneron shares have been trading around 27 times this year's earnings expectations. This sky-high multiple makes the stock extra sensitive to any forward outlook adjustments. Disparaging comments from Wall Street analysts citing potential competition for Dupixent from AnaptysBio (ANAB -4.20%) and its early-stage eczema candidate were all it took to knock Regeneron's price down a few pegs.

Now what

In the U.S. alone, around 3.2 million children have moderate to severe eczema, and the size of the adult population underserved by standard treatment is staggering. With an annual list price of around $36,000 in the U.S., this drug's sales potential is almost unlimited, at least in theory.

Unfortunately, Regeneron is becoming the poster child for a disturbing industry trend: End payers are pushing back harder than ever when it comes to pricey new drugs with big patient populations. Insurers and pharmacy benefits managers successfully stomped megablockbuster expectations for Sanofi and Regeneron's next-generation cholesterol drug Praluent. Investors will want to keep their eyes peeled for signs recently launched Dupixent can avoid the same fate when Regeneron reports third-quarter earnings on Wednesday, Nov. 8.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$594.90 (-0.28%) $-1.66
Sanofi Stock Quote
$50.04 (-0.28%) $0.14
AnaptysBio Stock Quote
$21.00 (-4.20%) $0.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.